Global News

Verastem changes its board of directors

Monday, June 20, 2016

Verastem focused on discovering and developing drugs to treat cancer, has announced several changes to the company’s board of directors. Michael Kauffman, M.D., Ph.D., who has served as a director since November 2012, will become lead director and Bruce J. Wendel will join the board as an independent director.

[Read More]

Don’t be hasty in clinical research decisions

Monday, June 20, 2016

The Pulse on Study Conduct by Elizabeth Weeks-Rowe

The ability to use good judgment and make sound decisions in clinical research is based on experience, communication and execution. Decision making is influenced by such factors as the familiarization with regulations that govern clinical research, successful management of investigational site relationships and corrective and preventative action with issues that affect patient safety and credible data (informed consent, protocol deviations, safety reporting).

[Read More]

Takeda, M2Gen to generate broad genomic data from consenting cancer patients

Monday, June 20, 2016

Takeda Pharmaceutical and M2Gen, a healthcare informatics solutions company, have established a new collaboration to generate broad genomic data from consenting cancer patients. Under the agreement, Takeda will help build the Oncology Research Information Exchange Network (ORIEN) Avatar Research Program based on the Total Cancer Care Protocol, a prospective observational study enrolling patients with various cancers, and access information generated under this program.

[Read More]

California Life Sciences Association expands advocacy team

Monday, June 20, 2016

The California Life Sciences Association (CLSA) has announced a new hire and several staff promotions in its advocacy team, further bolstering the organization’s government relations and communications efforts at the federal, state and local levels on behalf of California’s world-leading life sciences sector. CLSA is the nation’s largest statewide life sciences public policy and business solutions organization representing more than 750 of California’s life sciences innovators.

[Read More]

Veristat adds Mark Chang as SVP of Strategic Statistical Consulting

Friday, June 17, 2016

Veristat, a full service CRO, has strengthened its statistical consulting and adaptive design expertise with the appointment of Mark Chang, Ph.D., to the newly created position of senior vice president of Strategic Statistical Consulting. Dr. Chang will help clients evaluate and implement strategic, operational and technical efficiencies to advance products through the clinical trial and regulatory submission process.

[Read More]